The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria.
作者信息
Han Bing, Ji Jiang, Zhang Bo, Bai Hua, Zhou Daobin, Feng Feng, Huang Yan, Zhu Huijuan, Chen Limeng, Wu Zhihong, Jiang Xiuchun, Li Xuemei, Jia Qing, Chang Qing, Pan Hui, Peng Hua, Zheng Wenting, Huang Hui, Chen Zheng, Yang Chen, Chen Miao, Du Bin, Zhang Shuyang
机构信息
Peking Union Medical College Hospital, Beijing, China.
出版信息
Ann Hematol. 2022 Nov;101(11):2537-2539. doi: 10.1007/s00277-022-04933-5. Epub 2022 Aug 15.
Abstract
摘要
相似文献
1
The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria.
Ann Hematol. 2022 Nov;101(11):2537-2539. doi: 10.1007/s00277-022-04933-5. Epub 2022 Aug 15.
2
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Lancet Haematol. 2021 May;8(5):e344-e354. doi: 10.1016/S2352-3026(21)00028-4. Epub 2021 Mar 23.
3
Iptacopan (Fabhalta) for paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e171-e173. doi: 10.58347/tml.2024.1712e.
4
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria.
J Manag Care Spec Pharm. 2024 Jun;30(6):618-623. doi: 10.18553/jmcp.2024.30.6.618.
5
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply.
N Engl J Med. 2024 Jun 6;390(21):2033-2034. doi: 10.1056/NEJMc2404445.
6
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2024 Jun 6;390(21):2033. doi: 10.1056/NEJMc2404445.
7
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med. 2024 Jun 6;390(21):2032-2033. doi: 10.1056/NEJMc2404445.
8
Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Blood. 2023 Jan 5;141(1):116-120. doi: 10.1182/blood.2022017266.
9
Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.
Am J Hematol. 2008 Nov;83(11):881-3. doi: 10.1002/ajh.21265.
10
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.
引用本文的文献
1
Direct Oral Anticoagulants and Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Update on Evidence.
Cureus. 2024 Dec 31;16(12):e76702. doi: 10.7759/cureus.76702. eCollection 2024 Dec.
2
[Expert consensus on clonal screening and monitoring of complement inhibitor therapy in paroxysmal nocturnal hemoglobinuria (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):109-114. doi: 10.3760/cma.j.cn121090-20230927-00145.
3
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2949-2970. doi: 10.1007/s00210-024-03063-1. Epub 2024 Mar 26.
Zotero 插件